[Edaily Reporter Kim Seung-kwon ] #SAMSUNG EPIS HOLDINGS announced on the 1st that it held an opening ceremony for its China R&D (Research and Development) center on the 30th of last month. This center marks SAMSUNG EPIS HOLDINGS’ first overseas R&D hub.
The building housing the China R&D Center (Photo: SAMSUNG EPIS HOLDINGS)
The company established the center as a field-specific organization to secure a technology platform centered on antibody-drug conjugates (ADCs) and strengthen its new drug development capabilities.
SAMSUNG EPIS HOLDINGS explained that Changping District in Beijing, where the center is located, is home to the Zhongguancun Life Sciences Park—a biotechnology industrial complex—and is adjacent to Peking University and Tsinghua University, making it an ideal location for leveraging research infrastructure and human resources.
Kim Kyung-ah, President of SAMSUNG EPIS HOLDINGS, said, “Going forward, we will work closely with the Chinese biotech ecosystem and strive to continuously expand new business initiatives, such as the discovery of innovative drug candidates.”
As NVIDIA achieved record-high revenue for the 13th consecutive quarter, the company once again emphasized its collaboration with major memory manufacturers such as SamsungElectronics and SK hynix. Th…
#Shinsegae Co.,Ltd is accelerating the final stages of the spin-off involving siblings Chung Yong-jin and Chung Yu-kyung. Since establishing an independent management structure for the siblings in 201…
(Courtesy of SamsungElectronics)
SamsungElectronics(005930)unveiled the “Galaxy S26 FE (Fan Edition)” on the 27th, a device that incorporates a well-rounded selection of flagship features. This ne…
